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Allergy is an immunoglobulin E (IgE)-mediated hypersensitivity disease affecting more than 25% of the population \[[@bib0380]\]. Allergic patients suffer from a broad variety of symptoms (e.g., rhinoconjunctivitis, asthma, dermatitis, gastrointestinal symptoms, life-threatening systemic anaphylaxis) upon allergen contact. Allergen-specific immunotherapy (SIT), the therapeutic vaccination with the disease-causing allergens is a clinically effective treatment for allergy which unlike symptomatic pharmacotherapy, modifies the underlying pathological immune response and seems to have long-lasting effects \[[@bib0010]\]. In 1911 L. Noon published the first successful immunotherapy trial which he had performed in grass pollen-allergic patients using pollen extracts administered by subcutaneous immunization \[[@bib0015]\]. In his classical publication ([Figure 1](#fig0005){ref-type="fig"}) he referred to the work by W.P. Dunbar, who not only had identified pollen grains as allergen source but also had succeeded in producing antisera by immunizing animals with pollen extracts \[[@bib0385]\]. Moreover, Dunbar showed that these antisera prevented allergic symptoms when patients were exposed to allergens in provocation tests. The fact that vaccination with allergens can be used to treat a hypersensitivity disease is surprising. The dominant explanation for this effect is that SIT induces counter IgG responses towards the disease-causing allergens which interfere with allergen-specific IgE responses. The latter has been demonstrated in a classical study already in 1935 \[[@bib0025]\]. Since then, many studies support the concept that the induction of allergen-specific blocking IgG antibodies is a major mechanism of SIT but also cellular mechanisms are discussed and investigated \[[@bib0010]\].

Although SIT is a clinically effective treatment, it has been recognized that the use of natural allergen extracts for the preparation of the vaccines is a major bottleneck for its further development towards a broadly used treatment. In this context, several studies have demonstrated the poor quality of allergen extracts which may lack important allergens and show unpredictable compositions \[[@bib0030; @bib0035; @bib0040; @bib0045]\]. Another major problem of SIT is that the administration of allergens can cause severe side effects \[[@bib0045]\]. Therefore, SIT is limited to specially trained physicians, it requires the multiple application of increasing allergen doses to reach the therapeutically effective maintenance doses and thus only relatively few allergic patients can benefit from SIT.

However, during the last 25 years, molecular cloning techniques have enabled the isolation of allergen-encoding cDNAs from various allergen sources and the subsequent production of allergens in recombinant form \[[@bib0050]\]. Recombinant allergens have facilitated the investigation of the pathomechanisms of allergy using clinically relevant allergens in patients. *In vitro* and *in vivo* diagnostic tests based on recombinant allergens, epitopes and peptides have been developed which allow for a more precise diagnosis of allergy and monitoring of immune responses during treatment ([Figure 2](#fig0010){ref-type="fig"}) (reviewed in \[[@bib0050]\]). Most importantly, the availability of allergen sequences and structures has allowed the development of new sophisticated allergy vaccines which have entered successful clinical evaluation and hold promise that more effective, safe and convenient allergy vaccines become soon available and it even seems that prophylactic vaccination is on the horizon \[[@bib0050]\].

Allergen-based diagnosis and monitoring of immune responses: Towards better prescription and understanding of SIT mechanisms. {#sec0030}
=============================================================================================================================

Allergen-SIT is a form of therapeutic vaccination and hence requires that the disease-causing allergens are identified for prescription of the correct vaccine. Diagnostic tests based on recombinant allergen molecules allow the precise determination of IgE reactivities to the individual allergen molecules leading to better understanding of cross-reactivities \[[@bib0055]\]. Furthermore, component testing identifies the allergen sources primarily responsible for allergic sensitization in different populations and thus forms a basis for better prescription of SIT. A recent study demonstrated that the detailed knowledge of the molecular IgE reactivity profiles profoundly changed the prescription of allergy vaccines among allergologists \[[@bib0060]\]. Using diagnostic tests based on recombinant bee and wasp allergens devoid of cross-reactive carbohydrate epitopes \[[@bib0065]\] it was shown that it is possible to discriminate genuinely bee and wasp-sensitized patients from double-sensitized patients, allowing more precise prescription of venom SIT. In fact, clinically non-relevant cross-reactive carbohydrate epitopes were also shown to impair the diagnosis of cat allergy \[[@bib0070]\] which can be achieved with non-glycosylated recombinant cat allergens \[[@bib0075]\].

Several studies conducted in food allergic patients indicate that component-resolved allergy diagnosis allows predicting whether individuals are prone to develop mild or more severe manifestations of food allergy \[[@bib0080; @bib0085; @bib0090]\]. Such tests are useful for preventive measures such as diet and may pave the road towards vaccination against food allergy. In this context, clinical studies have shown that oral immunotherapy, may be effective for the treatment of milk, egg and peanut allergy \[[@bib0095; @bib0100; @bib0105]\]. Several studies highlight the usefulness of diagnostic allergy tests based on micro-arrayed allergens which allow the simultaneous detection of IgE reactivities against a large number of allergens with small blood samples \[[@bib0080; @bib0110; @bib0115]\].

Recombinant allergen components, epitopes and peptides have been used to study the effects of SIT in patients (reviewed in \[[@bib0010; @bib0045; @bib0050]\]). Studies using recombinant allergens for monitoring of SIT re-emphasized the importance of blocking IgG antibodies for the prevention of allergen-induced effector cell degranulation \[[@bib0120; @bib0125]\]. On the basis of the availability of allergen sequences it has become possible to produce MHCII tetramers for monitoring allergen-specific T cell responses in the course of disease and during SIT \[[@bib0130; @bib0135]\].

Mechanisms of SIT {#sec0010}
=================

Besides classical injection immunotherapy (SCIT) also other application routes for SIT have been investigated. Many clinical studies based on sublingual administration of allergens (SLIT) have been conducted and it seems that this treatment is clinically effective, albeit less than injection immunotherapy. Also the immunological mechanisms underlying SLIT are less well understood than those of SCIT. A recent study proposed that IgE-mediated allergen uptake by mucosal APCs may lead to an increased production of immunoregulatory cytokines like IL-10 and TGF-β \[[@bib0140]\]. Yet SLIT induces only low levels of allergen-specific IgG but rather boosts allergen-specific IgE \[[@bib0145]\]. By contrast, it has been demonstrated in immunotherapy trials using purified recombinant wildtype allergens for subcutaneous vaccination that the induction of allergen-specific IgG antibodies was associated with the reduction of symptoms, medication intake and sensitivity to the allergen \[[@bib0150]\]. Vaccination-induced allergen-specific IgG thus occupies the binding sites for IgE on the allergens and blocks allergen-induced effector cell activation \[[@bib0125]\] as well as IgE-facilitated antigen presentation of allergens to T cells \[[@bib0155]\]. The latter mechanism may explain the reduced allergen-specific T cell activation in SIT-treated patients as an antibody-mediated effect. Interestingly, it was suggested that besides epitope-specificity, affinity may play an important role for the effects of blocking antibodies \[[@bib0160]\]. Already in earlier SCIT trials with recombinant hypoallergenic allergen derivatives and CpG-modified allergens it has been shown that the induction of allergen-specific IgG is associated with a reduction of the boosts of allergen-specific IgE production occurring after seasonal allergen exposure and represents another important mechanism for the effects of SCIT \[[@bib0165; @bib0170]\]. The mechanisms underlying SCIT with hypoallergenic allergen-derivatives have been summarized in a recent review \[[@bib0390]\].

In addition to established subcutaneous injection of allergens and allergen-derivatives intralymphatic administration of allergy vaccines has been suggested for reducing side effects and obtaining increased allergen-specific IgG but the latter has not yet been convincingly demonstrated \[[@bib0180]\]. Furthermore, epicutaneous allergen administration has been proposed as an alternative route to subcutaneous injection. Studies performed in experimental animal models indicate that epicutaneous allergen application may have effects on systemic allergen-specific immune responses \[[@bib0185; @bib0190]\] but effects on systemic immunity have not been studied in allergic patients \[[@bib0195]\].

Studies performed with T cell epitope-containing peptides which do not induce allergen-specific IgG responses indicate that SIT may also selectively address allergen-specific T cell responses. The administration of peptides from the major cat allergen Fel d 1 induced a reduction of delayed type, presumably T cell-mediated symptoms \[[@bib0200]\]. The induction of IL-10 producing T regulatory cells and the existence of linked immunological suppression have been suggested as possible underlying mechanisms \[[@bib0205]\]. Indeed, it has been demonstrated in a TCR-transgenic model that Th1 cells as well as Fox p 3+ regulatory T cells are able to suppress the effector functions of Th2 cells \[[@bib0210; @bib0215]\]. However, the effects of T cell peptide therapy on allergen-induced mast cell degranulation and acute allergic inflammation observed in clinical trials are modest and deserve further investigation \[[@bib0220]\].

New molecules and strategies for SIT: sophisticated targeting of the immune system {#sec0015}
==================================================================================

When the sequences of the first major allergens became available and their T cell epitopes could be mapped using peptide technology, the concept of inducing T cell tolerance with non-IgE reactive but T cell epitope-containing peptides emerged as the first targeted molecular SIT approach \[[@bib0225; @bib0230]\]. Currently several immunotherapy studies with allergen-derived T cell peptides are ongoing of which a recent study performed for cat allergy showed beneficial effects on late phase allergic symptoms \[[@bib0200]\]. Although there is evidence for linked immunological suppression \[[@bib0205]\], it is very likely that the T cell peptide approach will require that several different allergen-derived peptides are included in the vaccine in order to cover the diverse spectrum of T cell epitopes recognized by allergic patients.

Several research groups have therefore developed recombinant hypoallergenic allergen derivatives which are characterized by reduced IgE reactivity but preserved T cell epitopes to reduce IgE-mediated side effects during SIT (reviewed in \[[@bib0390; @bib0235]\]). These molecules are made by reducing IgE reactivity and maintaining the spectrum of the T cell epitopes of the original wildtype allergens by various recombinant DNA technologies such as mutation, reassembly, or fragmentation. The first immunotherapy trial with recombinant allergens was actually performed with recombinant hypoallergenic derivatives of the major birch pollen allergen Bet v 1 eleven years ago. Meanwhile, successful phase III SIT trials with recombinant Bet v 1 hypoallergens have been performed \[[@bib0240]\]. The analyses of SCIT trials which have been performed with recombinant hypoallergenic allergen derivatives revealed the induction of allergen-specific blocking IgG antibodies as a major underlying mechanism. Several recombinant hypoallergens for the treatment of allergy to house dust mites, birch pollen and cat have been constructed and characterized in *in vitro* and experimental animal models recently \[[@bib0245; @bib0250; @bib0255; @bib0260; @bib0265; @bib0270]\]. Different strategies for their construction have been used such as reassembly of sequence elements \[[@bib0245; @bib0250; @bib0275]\], oligomerization to increase IgG responses \[[@bib0255]\], epitope grafting inducing altered fold \[[@bib0270]\], coupling to Vitamin D3 for immunomodulation \[[@bib0260]\], random PCR-based sequence evolution \[[@bib0280]\] and mutations \[[@bib0265]\].

Successful clinical SCIT trials have been performed with recombinant allergens made exactly as their natural counterparts for birch and grass pollen allergy \[[@bib0150; @bib0285]\]. These studies also demonstrated that clinical efficacy and reduction of sensitivity are associated with the development of allergen-specific IgG antibodies \[[@bib0240]\].

In the course of clinical studies performed with non-IgE-reactive T cell peptides and recombinant hypoallergenic allergen derivatives it has been recognized that allergen-derived T cell epitopes can induce late phase, non-IgE-mediated side effects. In an attempt to eliminate IgE as well as T cell-mediated side effects a new type of allergy vaccines has therefore been developed \[[@bib0050]\]. This approach is based on the identification of allergen peptides which are part of the major IgE binding sites on allergens but *per se* lack IgE and allergenic activity \[[@bib0290]\]. These peptides which are typically between 20 and 35 amino acids in length can either be coupled chemically to a carrier protein \[[@bib0295; @bib0300; @bib0395]\] or produced as recombinant fusion proteins with a carrier protein \[[@bib0310; @bib0315]\]. Immunization with carrier-bound allergen peptides induces and focuses IgG antibodies towards the IgE epitopes on allergens with the T cell help of the carrier protein and thus do not activate allergen-specific T cells. Since the presence of allergen-specific T cell epitopes is reduced in these vaccines they should bypass T cell-mediated side effects \[[@bib0045]\]. Viral carrier proteins have been suggested in order to achieve immunomodulation and to induce a beneficial antiviral immunity in addition to protection against allergens \[[@bib0320]\]. A similar approach aiming at the induction of allergen-specific IgG antibodies is based on the use of allergen mimotopes \[[@bib0325]\].

Since allergen-specific IgG antibodies seem to play a major role in antagonizing allergic immune responses, passive immunization with allergen-specific IgG antibodies has emerged as another possibility for allergy vaccination \[[@bib0330]\]. In fact, human allergen-specific IgG antibodies capable of blocking even polyclonal IgE recognition of allergens have been developed \[[@bib0335; @bib0340]\]. Moreover, it has been demonstrated in experimental animal models that maternal immunization generates allergen-specific IgG which is transmitted to the offspring and can prevent allergic sensitization \[[@bib0345; @bib0350; @bib0355]\].

On the basis of the finding that transfer of hematopoetic stem cells expressing major allergens can induce robust allergen-specific tolerance in a preventive model of allergy \[[@bib0360; @bib0365]\], membrane-anchored and secreted allergen-expressing stem cells have been recently engineered to delineate the mechanisms of tolerance \[[@bib0370]\]. Gene therapy is an interesting preventive approach for allergy but will require the simultaneous assembly of major allergen epitopes recognized in certain populations and it will be necessary to develop safe treatment protocols \[[@bib0370]\] ([Figure 2](#fig0010){ref-type="fig"}).

Another interesting approach for immunomodulation is vaccination with allergen-encoding RNA which in experimental animal models has been shown to prevent allergic sensitization for several allergens \[[@bib0375]\].

Outlook: broad therapeutic vaccination and prophylactic vaccines? {#sec0020}
=================================================================

[Table 1](#tbl0005){ref-type="table"} provides an overview of different strategies for SIT based on their putative immunological mechanisms. Certain strategies such as SCIT with recombinant allergen, hypoallergens, T cell peptides and carrier-bound allergen peptides are already in clinical evaluation and hold promise that allergen molecule-based vaccines will be soon available for broad, safe and convenient therapeutic vaccination. However, more controlled immunotherapy studies with defined allergen, allergen derivatives and epitopes are needed to further delineate the mechanisms of SIT and optimize the vaccines. Studies performed in experimental animal models and non-allergic individuals with engineered allergen derivatives and epitopes will be necessary to develop prophylactic vaccination and tolerance induction strategies for the prevention of allergies which may ultimately halt the allergy pandemic.
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![Classical publication of the first immunotherapy trial conducted by L. Noon from 1911, highlighting the earlier experiments performed by WP Dunbar supporting that SIT is a vaccine approach. Reprinted from \[[@bib0015]\] with permission.](gr1){#fig0005}
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